Show simple item record

dc.contributor.authorBernal-Martinez, Leticia 
dc.contributor.authorGil, Horacio 
dc.contributor.authorRivero-Menendez, Olga 
dc.contributor.authorGago Prieto, Sara 
dc.contributor.authorCuenca-Estrella, Manuel 
dc.contributor.authorMellado, Emilia 
dc.contributor.authorAlastruey-Izquierdo, Ana 
dc.date.accessioned2020-06-11T09:08:22Z
dc.date.available2020-06-11T09:08:22Z
dc.date.issued2017
dc.identifier.citationAntimicrob Agents Chemother . 2017 Nov 22;61(12):e01083-17.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/10338
dc.description.abstractThe global emergence of azole-resistant Aspergillus fumigatus strains is a growing public health concern. Different patterns of azole resistance are linked to mutations in cyp51A Therefore, accurate characterization of the mechanisms underlying azole resistance is critical to guide selection of the most appropriate antifungal agent for patients with aspergillosis. This study describes a new sequencing-free molecular screening tool for early detection of the most frequent mutations known to be associated with azole resistance in A. fumigatus PCRs targeting cyp51A mutations at positions G54, Y121, G448, and M220 and targeting different tandem repeats (TRs) in the promoter region were designed. All PCRs were performed simultaneously, using the same cycling conditions. Amplicons were then distinguished using a high-resolution melting assay. For standardization, 30 well-characterized azole-resistant A. fumigatus strains were used, yielding melting curve clusters for different resistance mechanisms for each target and allowing detection of the most frequent azole resistance mutations, i.e., G54E, G54V, G54R, G54W, Y121F, M220V, M220I, M220T, M220K, and G448S, and the tandem repeats TR34, TR46, and TR53 Validation of the method was performed using a blind panel of 80 A. fumigatus azole-susceptible or azole-resistant strains. All strains included in the blind panel were properly classified as susceptible or resistant with the developed method. The implementation of this screening method can reduce the time needed for the detection of azole-resistant A. fumigatus isolates and therefore facilitate selection of the best antifungal therapy in patients with aspergillosis.es_ES
dc.description.sponsorshipThis study was financed by a research project from the Fondo de Investigación Sanitaria (FIS) (project PI13/02145). It was supported by Plan Nacional de I+D+i and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, and the Spanish Network for Research in Infectious Diseases (REIPI grant RD12/0015), cofinanced by the European Development Regional Fund. L.B.-M. has a research contract from the Spanish Network for Research in Infectious Diseases (REIPI grant RD12/0015). O.R.-M. holds a predoctoral fellowship from the Fondo de Investigaciones Sanitarias (grant FI14CIII/00025). S.G. was supported by a research fellowship from the Fondo de Investigaciones Sanitarias of the Spanish Ministry of Science and Innovation (grant FI10/00464). E.M. was supported by a project from the Spanish Fondo de Investigación Sanitaria (FIS grant PI15CIII/00019).es_ES
dc.language.isoenges_ES
dc.publisherAmerican Society for Microbiology (ASM) es_ES
dc.type.hasVersionAMes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subject.meshAntifungal Agents es_ES
dc.subject.meshAspergillosis es_ES
dc.subject.meshAspergillus fumigatus es_ES
dc.subject.meshCytochrome P-450 Enzyme System es_ES
dc.subject.meshDrug Resistance, Fungal es_ES
dc.subject.meshFungal Proteins es_ES
dc.subject.meshHumans es_ES
dc.subject.meshMicrobial Sensitivity Tests es_ES
dc.subject.meshNucleic Acid Denaturation es_ES
dc.subject.meshPolymerase Chain Reaction es_ES
dc.subject.meshPromoter Regions, Genetices_ES
dc.subject.meshTandem Repeat Sequences es_ES
dc.titleDevelopment and Validation of a High-Resolution Melting Assay To Detect Azole Resistance in Aspergillus fumigatus.es_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.identifier.pubmedID28893791es_ES
dc.format.volume61es_ES
dc.format.number12es_ES
dc.identifier.doi10.1128/AAC.01083-17es_ES
dc.contributor.funderInstituto de Salud Carlos III 
dc.contributor.funderRETICS-Investigación en Patología Infecciosa (REIPI-ISCIII) (España) 
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) 
dc.description.peerreviewedes_ES
dc.identifier.e-issn1098-6596es_ES
dc.relation.publisherversionhttps://doi.org/10.1128/AAC.01083-17es_ES
dc.identifier.journalAntimicrobial agents and chemotherapyes_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/PI13/02145es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/RD12/0015es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/FI14CIII/00025es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/FI10/00464es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/PI15CIII/00019es_ES
dc.rights.accessRightsopen accesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-CompartirIgual 4.0 Internacional
This item is licensed under a: Atribución-NoComercial-CompartirIgual 4.0 Internacional